The intermediate hepatocellular carcinoma stage: Should treatment be expanded?

Digestive and Liver Disease

Volumn 42, Issue SUPPL. 3, 2010, Pages S258-S263

  Piscaglia, Fabio ^a   Bolondi, Luigi ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Multifocal HCC; Systemic treatment; TransArterial ChemoEmbolization (TACE); Treatment of recurrence

Indexed keywords

PLACEBO; SORAFENIB;

ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; MEDICAL DECISION MAKING; PATIENT ASSESSMENT; PRIORITY JOURNAL; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; PATHOLOGY;

CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING;

EID: 77953691839     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(10)60514-2     Document Type: Article

References (41)

1. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985, 56:918-928.
2. TMN classification of malignant tumours 2007, (UICC) IUAC, Wiley-Liss, New York.
3. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 2000, 31:840-845. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma.
4. Kudo M, Chung H, Osaki Y Prognostic staging system for hepatocelhilar carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003, 38:207-215.
5. Leung TW, Tang AM, Zee B, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002, 94:1760-1769.
6. Llovet JM, Bru C, Bruix J Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19:329-338.
7. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med 1995, 332:1256-1261. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma.
8. Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998, 27:1578-1583.
9. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002, 359:1734-1739.
10. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35:1164-1171.
11. Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 1998, 29:129-134.
12. Grieco A, Pompili M, Caminiti G, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005, 54:411-418.
13. Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005, 41:707-716.
14. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34.
15. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
16. Bruix J, Sherman M Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
17. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Nati Cancer Inst 2008, 100:698-711.
18. Hoshida Y, Toffanin S, Lachenmayer A, et al. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010, 30:35-51.
19. Camma C, Di Marco V, Cabibbo G, et al. Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. Aliment Pharmacol Ther 2008, 28:62-75.
20. Cabibbo G, Enea M, Attanasio M, et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010, 51:1274-1283.
21. Llovet JM, Bruix J Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003, 37:429-442.
22. Llovet JM, Bruix J Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008, 48(Suppl l):S20-S37.
23. Camma C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002, 224:47-54.
24. Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010, 33:41-52.
25. Ahrar K, Gupta S Hepatic artery embolization for hepatocellular carcinoma: technique, patient selection, and outcomes. Surg Oncol Clin N Am 2003, 12:105-126.
26. Pleguezuelo M, Germani G, Marelli L, et al. Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2008, 2:761-784.
27. Sikander A, Sadashiv S, Ronald S, et al. Transarterial chemoembolization in a patient with recurrent hepatocellular carcinoma and portal vein thrombosis: a case report and review of the literature. Am J Clin Oncol 2005, 28:638-639.
28. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24:4293-4300.
29. Ozenne V, Paradis V, Pernot S, et al. Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol 2010, Mar 17. [Epub ahead of print].
30. Worns MA, Weinmann A, Pfingst K, et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009, 43:489-495.
31. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010, 138:52-64.
32. Carr BI, Kondragunta V, Buch SC, et al. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 2010, 116:1305-1314.
33. D'Avola D, Lnarrairaegui M, Bilbao JI, et al. A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma. Hepatogastroen-terology 2009, 56:1683-1688.
34. Piscaglia F, Camaggi V, Ravaioli M, et al. A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system. Liver Transpl 2007, 13:857-866.
35. Piscaglia F, Gianstefani A, Righini R, et al. Selecting patients with hepatocellular carcinoma for transplantation. Liver Transpl 2007, 13:1203.
36. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-699.
37. Peck-Radosavljevic M, Greten TF, Lammer J, et al. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2010, 22:391-398.
38. Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of Sorafenib in patients with hepatocellular carcinoma (HCC): subanalysis of SHARP trial based on Barcelona Clinic Liver Cancer (BCLC) stage. J Hepatol 2009, 50(Suppl 1):S28.
39. Minami Y, Kawasaki T, Kudo M, et al. Treatment of large and/or multiple hepatic malignancies: open surgical approaches of radiofrequency ablation. Hepatogastroenterology 2007, 54:2358-2360.
40. Dawson LA, Guha C Hepatocellular carcinoma: radiation therapy. Cancer J 2008, 14:111-116.
41. Marelli L, Stigliano R, Triantes C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective?. A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007, 30:6-25.